ScreenerHero

CRDFCardiff Oncology, Inc.

NAS · US · Healthcare · Biotechnology · cardiffoncology.com
0.8801USD-1.98%Mkt Cap: 68.47M $P/E: —

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap68.47M $
Enterprise Value36.63M $
Revenue (TTM)508.00K $
Gross Profit-34.82M $
Net Income (TTM)-45.85M $
Revenue/Share0.0070 USD
Last Price0.8801 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees30
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS14147L1089
Valuation
P/E (Trailing)—
P/E (Forward)-1.55
PEG—
EV/EBITDA-0.87
EV/Revenue72.11
P/S139.16
P/B2.35
EPS (TTM)-0.61
EPS (Forward)-0.58
52W Range
0.75665% of range3.310
52W High3.310 USD
52W Low0.7566 USD
Profitability
Gross Margin0.00%
Oper. Margin-9245.19%
EBITDA Margin0.00%
Profit Margin-7732.04%
ROE-101.02%
ROA-74.09%
Growth
Revenue Growth-14.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.92M $
CapEx (TTM)44.00K $
FCF Margin-4784.30%
FCF Yield-35.50%
Net Debt-34.06M $
Net Debt/EBITDA0.81
Balance Sheet
Debt/Equity0.02
Current Ratio3.30
Quick Ratio3.21
Book Value/Sh0.3870 USD
Cash/Share0.4440 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 20, 2019
Splits
Last Split1:6
Split DateFeb 20, 2019
Analyst Consensus
Rating2.4 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.100 USD
Upside (mean)+479.5%
Target Range1.200 USD – 12.00 USD
$1.200+479.5% to mean$12.00
# Analysts7
Ownership
Shares Out.77.80M
Float75.36M
Insiders6.12%
Institutions21.25%
Short Interest
Short Ratio7.5d
Short % Float16.00%
Short % Out.15.67%
Shares Short12.19M
Short (prev mo.)12.81M
Technical
SMA 501.094 (-19.6%)
SMA 2001.784 (-50.7%)
Beta1.44
S&P 52W Chg18.16%
Avg Vol (30d)1.37M
Avg Vol (10d)717.52K
Technical Indicators
RSI (14)37.0
MACD-0.0458
MACD Signal-0.0568
MACD Hist.+0.0110
BB Upper1.063 USD
BB Middle0.9153 USD
BB Lower0.7673 USD
BB Width32.33%
ATR (14)0.0785 USD
Vol Ratio (20d)0.75x